A61K 48/0016
Wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e.
Official title: {wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid}
A61K48/0016 (Wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e.) appears on 95 US grants and 289 published applications in this corpus.
Search patents in A61K- Granted patents
- 95
- Published applications
- 289
- Assignees
- 169
- Inventors
- 560
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 2 |
| 2003 | 0 | 3 |
| 2004 | 0 | 5 |
| 2005 | 0 | 5 |
| 2006 | 1 | 4 |
| 2007 | 1 | 2 |
| 2008 | 0 | 2 |
| 2009 | 1 | 4 |
| 2010 | 0 | 2 |
| 2011 | 0 | 5 |
| 2012 | 0 | 1 |
| 2013 | 1 | 2 |
| 2014 | 1 | 8 |
| 2015 | 2 | 4 |
| 2016 | 2 | 10 |
| 2017 | 1 | 9 |
| 2018 | 8 | 28 |
| 2019 | 8 | 39 |
| 2020 | 9 | 19 |
| 2021 | 13 | 22 |
| 2022 | 13 | 8 |
| 2023 | 11 | 23 |
| 2024 | 7 | 36 |
| 2025 | 12 | 32 |
| 2026 | 3 | 14 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for treating cancer with anti-CD33 immunotherapy25 Aug 2026US 12,714,750 B2Lentigen Technology, Inc.
- 5′-modified carbocyclic ribonucleotide derivatives and methods of use26 May 2026US 12,636,301 B2Sanegene Bio USA Inc.
- Oligonucleotide compositions and methods thereof26 May 2026US 12,637,672 B2Wave Life Sciences Ltd.
- Non-immunogenic circular, non-viral DNA vectors18 Nov 2025US 12,473,567 B2Rampart Bioscience, Inc.
- Non-immunogenic circular, non-viral DNA vectors18 Nov 2025US 12,473,568 B2Rampart Bioscience, Inc.
- Respiratory vectors and uses thereof20 Aug 2026US 2026/0242803 A1Aldevron, LLC
- Methods and compositions for transducing hematopoietic cells2 Jul 2026US 2026/0185058 A1Massachusetts Institute of Technology
- Scaffold matrix attachment regions for gene therapy4 Jun 2026US 2026/0152759 A1Summation Bio, Inc.
- Gene editing systems and uses thereof28 May 2026US 2026/0144898 A1Correctsequence Therapeutics (Shanghai) Co., Ltd
- Biologic agents and methods of use7 May 2026US 2026/0124227 A1SonoThera, Inc.
Most cited
By later US patents
- Means and method for inducing exon-skipping148US 8,361,979 B2Academisch Ziekenhuis Leiden · 2013
- Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure135US 7,534,879 B2Academisch Ziekenhuis Leiden · 2009
- Modulation of exon recognition in pre-mRNA by interfering RNA structure105US 8,759,507 B2Academisch Ziekenhuis Leiden · 2014
- Oligonucleotide compositions and methods thereof62US 10,450,568 B2Wave Life Sciences Ltd. · 2019
- Method for treating ischemic tissue58US 6,121,246 ASt. Elizabeth's Medical Center of Boston, Inc. · 2000